Chemotherapy in patients with castration-resistant prostate cancer

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 161-171

  Meulenbeld, Hielke J ^a   Hamberg, Paul ^a   de Wit, Ronald ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CLODRONIC ACID; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; SATRAPLATIN; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANALGESIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEART DISEASE; HUMAN; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK FACTOR; SENSORY NEUROPATHY; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 70349139601     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70029-2     Document Type: Article

References (60)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Scher H.I., Halabi S., Tannock I.F., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
4. Winquist E., Waldron T., Berry S., et al. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 6 (2006) 112 Review.
5. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 188-190
6. Osoba D., Tannock I.F., Ernst D.S., and Neville A.J. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17 (1999) 1654-1663
7. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
8. Tannock F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351 (2004) 1502-1512
9. Tannock I.F. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?. J Clin Oncol 3 (1985) 1013-1021
10. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
11. Picus J., and Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 Suppl.17 (1999) 14-18
12. Berry W., Dakhil S., Gregurich M.A., and Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 Suppl.15 (2001) 8-15
13. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273-1279
14. Petrylak D.P., Macarthur R.B., O'Connor J., et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17 (1999) 958-967
15. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CAL GB 9780. J Clin Oncol 19 (2001) 2509-2516
16. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Laufer M., Zahurak M., and Eisenberger M.A. Phase II evaluation of docetaxel plus one-day oral estramustine in the treatment of patients with androgen independent prostate carcinoma. Cancer 94 (2002) 1457-1465
17. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
18. Oudard S., Banu E., Beuzeboc P., et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 3343-3351
19. Eymard J.C., Priou F., Zannetti A., et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18 (2007) 1064-1070
20. Machiels J.P., Mazzeo F., Clausse M., et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 10 (2008) 5261-5268
21. Hamberg P., Verhagen P.C.M.S., and de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?. Eur J Cancer 44 (2008) 1193-1197
22. De Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. Eur J Cancer 41 (2005) 502-507
23. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Results from ASCENT, a double blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Paper presented at: American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium (2006) Abstract 216.
24. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
25. Halabi S., Vogelzang N.J., Kornblith A.B., et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26 (2008) 2544-2549
26. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396-6403
27. Armstrong A.J., Halabi S., Tannock I.F., de Wit R., George D.J., and Eisenberger M. Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. Genitourinary Cancers Symposium (2009) abstract.
28. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., Tannock I.F., and on behalf of the TAX-327 investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14 (2008) 2763-2767
29. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
30. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006) 516-521
31. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 (2007) 3965-3970
32. Thakkar S.G., Choueiri T.K., and Garcia J.A. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep 8 (2006) 108-113
33. Banerjee S., Hussain M., Wang Z., et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 67 (2007) 3818-3826
34. Picus J., Halabi S., Rini B., et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer:initial results of CALBG 90006. Proc Am Soc Clin Oncol (2003) abstract #1578.
35. Schwartz G.G., Oeler T.A., Uskokovic, and Bahnson R. Human prostate cancer cells: Inhibition of proliferation by vitamin D anologs. Anticancer Res 14 (1994) 1077-1081
36. Hershberger P.A., Yu W.D., Modzelewski R.A., Rueger R.M., John-son C.S., and Trump D.L. Calcitriol(1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7 (2001) 1043-1051
37. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25 (2007) 669-674
38. http://www.drugs.com/news/cell-genesys-halts-vital-2-gvax-trial-advanced-prostate-cancer-13371.html
39. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
40. Clarke N.W., McClure J., and George N.J. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 24 (1993) 286-290
41. Clarke N.W., McClure J., and George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. BrJUrol 68 (1991) 74-80
42. Ernst D.S., Tannock I., Venner P., et al. Randomized, double blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21 (2003) 3335-3342
43. Small E.J., Smith M.R., Seaman J.J., et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pein in men with metastatic prostate cancer. J Clin Oncol 21 (2003) 4277-4284
44. Saad F., Gleason D.M., Murray R., et al., for the Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
45. Saad F., Gleason D.M., Murray R., et al., for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95 (2003) 879-882
46. Dunn C.J., and Goa K.L. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61 (2001) 685-712
47. Sasaki A., Boyce B.F., Story B., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55 (1995) 3551-3557
48. Hall D.G., and Stocia G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9 (1994) 221-230
49. Boissier S., Magnetto S., Frappart L., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 (1997) 3890-3894
50. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami-H A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84 (2001) 1126-1134
51. http://www.ikcnet.nl/trials/index.php?id=112
52. Berthold D.R., Sternberg C.N., and Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23 (2005) 8247-8252
53. Michels J., Montemurro T., Kollmannsberger C., Murray N., and Chi K.N. First-and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?. Proc Am Soc Clin Oncol (2005) abstract #405s.
54. Oh W., Manola J., Babcic V., et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Proc Am Soc Clin Oncol (2005) abstract #406s.
55. Berthold D.R., Pond G.R., de Wit R., Eisenberger M., Tannock I.F., and On behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19 (2008) 1749-1753
56. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 (2007) 556-563
57. Sternberg C.N., Petrylak D., Witjes F., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Proc Am Soc Clin Oncol (2007) abstract #5019.
58. Sartor A.O., Petrylak P.D., Witjes J.A., et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Proc Am Soc Clin Oncol (2008) abstract #5003.
59. Danila D.C., Rathkopf D.E., Morris M.J., et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. Proc Am Soc Clin Oncol (2008) abstract #5019.
60. Attard G., Reid A., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571